Recent Advances in Employment Practices across Industries in India

Employment practices liability is an area that deals with wrongful termination, sexual harassment, discrimination, invasion of privacy, false imprisonment, breach of contract, emotional distress, and wage and hour law violations.As one of the most promising future world markets, India attracts many workers from abroad. Thriving IT centers such as Bangalore, Madras or Hyderabad offers great career opportunities for expatriates.Working in India demonstrates the willingness to work in a new culture and international market. As India’s importance in world economy increases, work experience in this country will become increasingly profitable

Dynamic Characteristics of PV System in Shaded/Un-shaded Portions Using MPPT Algorithm

In this paper, a combined low cost high efficiency converter and maximum peak power tracker has been presented. The maximum power point tracker system consists of DC-DC boost converter and PWM. PWM generates high quality sinusoidal line current. The suitable duty ratio for the boost converter will force the PV to work around the optimum voltage. The power generated by a PV cell depends on the operating voltage of the array, its voltage-current and voltage-power characteristic curves specify a unique operating point at which maximum possible power is delivered and the array is operated at its highest efficiency. One of the problems in designing efficient PV systems is to track the maximum power operating point for varying solar irradiance levels and ambient conditions. The output power produced by the PV panel is non-linear and changes with the solar irradiation and the ambient temperature. Therefore, a maximum power point tracking controller is needed to optimize the photovoltaic output power. A dc-dc converter is used to match the PV system to the load and to operate solar array at maximum power point .The perturbation and observation algorithm which is often employed to track the maximum power point This algorithm is selected due to its ability to withstand against any parameter variation and having a very high efficiency. As a result, by variation of the temperature and the insolation, the algorithm still managed to track the MPP successfully

Pedestrian Trajectory Prediction with Structured Memory Hierarchies

This paper presents a novel framework for human trajectory prediction based on multimodal data (video and radar). Motivated by recent neuroscience discoveries, we propose incorporating a structured memory component in the human trajectory prediction pipeline to capture historical information to improve performance. We introduce structured LSTM cells for modelling the memory content hierarchically, preserving the spatiotemporal structure of the information and enabling us to capture both short-term and long-term context. We demonstrate how this architecture can be extended to integrate salient information from multiple modalities to automatically store and retrieve important information for decision making without any supervision. We evaluate the effectiveness of the proposed models on a novel multimodal dataset that we introduce, consisting of 40,000 pedestrian trajectories, acquired jointly from a radar system and a CCTV camera system installed in a public place. The performance is also evaluated on the publicly available New York Grand Central pedestrian database. In both settings, the proposed models demonstrate their capability to better anticipate future pedestrian motion compared to existing state of the art.Comment: To appear in ECML-PKDD 201

Gold Nanoparticles Based Enzyme Biosensor for the Detection of Chloramphenicol

Chronic use of chloramphenicol (CAM) antibiotic leads to anaemia and bone marrow suppression resulting in 40 – 50% mortality. Hence, there is a need to develop an economical, fast and convenient method to detect CAM in milk, honey, shrimp and other aquaculture products. In the current method, coenzyme A was used to indirectly quantify CAM (since it is the cofactor product of the acetylation reaction of CAM). Coenzyme A (CoASH) was used to stabilize gold nanoparticles which were characterized by studying their extinction spectra. The reductant concentration and synthesis time were optimized. With optimized parameters the proposed system could detect CoASH up to 0.1 nM in buffer, with a linear range of detection from 0.1 μM to 1 mM

A model to assess the technological level of small businesses

none2In this paper we present a three-dimensional framework (named Cu- be of Corporate Technological Level – CCTL) to evaluate the technological po- sition of small enterprises from different points of view. This framework has been developed from existing tools with similar goals, already proposed by oth- er authors. Compared to existing ones, this framework differs primarily for the inclusion of a collaborative perspective. It reflects the distinctive features of the latest interactive and web 2.0 tools (chat, blogs, forums, ...), that allow compa- nies to manage their relationships with the external stakeholders of the supply chain. The proposed framework has been applied to a sample of small business- es to test its validity. Some business cases with different positions in the Cube are described.This paper is the joint effort of the authors. Francesca Maria Cesaroni developed sections 1, 2 and 5 and Domenico Consoli sections 3 and 4.openF.M.Cesaroni; D.ConsoliCesaroni, FRANCESCA MARIA; D., Consol

Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease:analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies

Background Individuals with diabetes often have high levels of atherogenic lipoproteins and cholesterol reflected by elevated low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), and LDL particle number (LDL-PN). The presence of atherosclerotic cardiovascular disease (ASCVD) increases the risk of future cardiovascular events. We evaluated the efficacy and safety of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, alirocumab, among individuals with type 2 diabetes (T2DM), high LDL-C or non-HDL-C, and established ASCVD receiving maximally tolerated statin in ODYSSEY DM-DYSLIPIDEMIA (NCT02642159) and DM-INSULIN (NCT02585778). Methods In DM-DYSLIPIDEMIA, individuals with T2DM and mixed dyslipidemia (non-HDL-C ≥ 100 mg/dL; n = 413) were randomized to open-label alirocumab 75 mg every 2 weeks (Q2W) or usual care (UC) for 24 weeks, with UC options selected before stratified randomization. In DM-INSULIN, insulin-treated individuals with T2DM (LDL-C ≥ 70 mg/dL; n = 441) were randomized in a double-blind fashion to alirocumab 75 mg Q2W or placebo for 24 weeks. Study participants also had a glycated hemoglobin < 9% (DM-DYSLIPIDEMIA) or < 10% (DM-INSULIN). Alirocumab dose was increased to 150 mg Q2W at week 12 if week 8 LDL-C was ≥ 70 mg/dL (DM-INSULIN) or non-HDL-C was ≥ 100 mg/dL (DM-DYSLIPIDEMIA). Lipid reductions and safety were assessed in patients with ASCVD from these studies. Results This analysis included 142 DM-DYSLIPIDEMIA and 177 DM-INSULIN participants with ASCVD, including 95.1% and 86.4% with coronary heart disease, and 32.4% and 49.7% with microvascular diabetes complications, respectively. At week 24, alirocumab significantly reduced LDL-C, non-HDL-C, ApoB, and LDL-PN from baseline versus control. This translated into a greater proportion of individuals achieving non-HDL-C < 100 mg/dL (64.6% alirocumab/23.8% UC [DM-DYSLIPIDEMIA]; 65.4% alirocumab/14.9% placebo [DM-INSULIN]) and ApoB < 80 mg/dL (75.1% alirocumab/35.4% UC and 76.8% alirocumab/24.8% placebo, respectively) versus control at week 24 (all P < 0.0001). In pooling these studies, 66.4% (alirocumab) and 67.0% (control) of individuals reported treatment-emergent adverse events. The adverse event pattern was similar with alirocumab versus controls. Conclusions Among individuals with T2DM and ASCVD who had high non-HDL-C/LDL-C levels despite maximally tolerated statin, alirocumab significantly reduced atherogenic cholesterol and LDL-PN versus control. Alirocumab was generally well tolerated